pharmaphorum September 25, 2024
Flagship Pioneering-backed artificial intelligence start-up Generate:Biomedicines has attracted another big pharma partnership, this time with Novartis.
The wide-ranging deal, worth up to $1 billion, covers multiple targets and disease areas and focuses on the discovery and development of protein-based therapeutics using Generate’s generative AI (GenAI) platform. Novartis is paying an upfront fee of $50 million to get the ball rolling and taking a $15 million stake in Generate.
The Massachusetts-based biotech’s approach involves teasing out the three-dimensional structure of human proteins, including how they are folded, to determine function – something that is almost impossible to work out simply from an amino acid sequence.
From there, its drug discovery engine can be used to predict the structures of drugs that...
Today's Sponsors
Today's Sponsor